Netherlands-based Royal Philips has partnered with US-based computational pathology solutions provider Paige to bring clinical-grade artificial intelligence (AI) technologies into routine pathological practice.
Pathologists will leverage these AI-powered technologies to precisely detect, quantify and characterise cancer cells, delivering improved patient care.
With the advancement in personalised medicine and surge in the number of cancer cases, the complexity of pathology diagnostics has increased, Philips noted.
By utilising advanced imaging analysis and workflow software, pathologists can quickly diagnose digital images of tissue samples, ultimately increasing the speed and accuracy of cancer diagnostics.
Philips’s digital pathology solutions are in use at various pathology laboratories, replacing the standard glass slide-based system.
Digital images enable the pathologists to detect and localise prostate cancer using the CE marked Paige Prostate software, offering the pathologists data, which they can apply during the assessment of prostate biopsies.
Philips digital and computational pathology business leader Marlon Thompson said: “We want to empower pathologists with the latest computational pathology solutions to enhance the diagnosis and treatment of cancer.
“Through our open digital pathology platform approach, we team up with leading computational pathology solution providers, such as Paige, to create the ultimate end-to-end oncology workflow for our customers.”
Philips intends to make Paige Prostate available to European pathology labs by next year.
By combining Paige Prostate with Philips IntelliSite Pathology Solution, the two entities aim to provide an intuitive digital and computational workflow to pathology laboratories.
Paige CEO Leo Grady said: “Pathology is transforming into a digital discipline and holds a strong promise for using AI solutions to aid, streamline, and enhance decision-making. Together with digital pathology providers, starting with Philips, one of the leaders in the clinical digital pathology space, we want to convert this promise into a clinical reality that supports pathologists and their patients.”